2013
- Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild type receptor. Tonia Aristotelous, Seungkirl Ahn, Arun K. Shukla, Sylwia Gawron, Maria F. Sassano, Alem W. Kahsai, Laura M. Wingler, Xiao Zhu, Prachi Tripathi-Shukla, Xi-Ping Huang, Jennifer Riley, Jérémy Besnard, Kevin D. Read, Bryan L. Roth, Ian H. Gilbert, Andrew L. Hopkins, Robert J. Lefkowitz and Iva Navratilova. ACS Med Chem Letts (2013), Just Accepted, Publication Date (Web): September 4, 2013, DOI: 10.1021/ml400289e
2012
-
Automated design of ligands to polypharmacological profiles. Jérémy Besnard, Gian Filippo Ruda, Vincent Setola, Keren Abecassis, Ramona M. Rodriguiz, Xi-Ping Huang, Suzanne Norval, Maria F. Sassano, Antony I. Shin, Lauren A. Webster, Frederick R. C. Simeons, Laste Stojanovski, Annik Prat, Nabil G. Seidah, Daniel B. Constam, G. Richard Bickerton, Kevin D. Read, William C. Wetsel, Ian H. Gilbert, Bryan L. Roth, Andrew L. Hopkins Nature (2012) 492, 215–220
-
-
What Can We Learn from the Evolution of Protein-Ligand Interactions to Aid the Design of New Therapeutics? Alicia P. Higueruelo, Adrian Schreyer, G. Richard Bickerton, Tom L. Blundell, Will R. Pitt PLoS ONE (2012) 7(12): e51742
-
-
Quantifying the chemical beauty of drugs. G Richard Bickerton, Gaia V Paolini, Jérémy Besnard, Sorel Muresan, Andrew L Hopkins Nature Chemistry (2012) 4(2), 90-98
-
Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. Ross A. Paveley, Nuha Mansour, Irene Hallyburton, Leo Bleicher, Alex Benn, Ivana Mikic, Alessandra Guidi, Ian H.Gilbert, Andrew L. Hopkins, Quentin D. Bickle, PLoS Neglected Tropical Diseases (2012), 6(7), e1762
-
Biosensor-based approach to the identification of protein kinase ligands with dual-site modes of action. Navratilova I, Macdonald G, Robinson C, Hughes S, Mathias J, Phillips C, Cook A. J Biomol Screen. 2012 Feb;17(2):183-93
2011
-
Rapid Analysis of Pharmacology for Infectious Diseases. Andrew L. Hopkins, G. Richard Bickerton, Ian M. Carruthers, Stephen K. Boyer, Harvey Rubin, John P. Overington. Current Topics in Medicinal Chemistry 11(10), 1292-1300(9)
-
Screening for GPCR Ligands Using Surface Plasmon Resonance. Iva Navratilova, Jeremy Besnard, Andrew L. Hopkins. ACS Medicinal Chemistry Letters Article ASAP
-
MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases. Filippi BM, de Los Heros P, Mehellou Y, Navratilova I, Gourlay R, Deak M, Plater L, Toth R, Zeqiraj E, Alessi DR. EMBO J. (2011) 30(9):1730-41.
-
Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. G Richard Bickerton, Alicia Higueruelo, Tom L Blundell BMC Bioinformatics (2011) 12(313).
2010
-
Fragment Screening by Surface Plasmon Resonance. Iva Navratilova and Andrew L. Hopkins, ACS Med Chem Letters (2010) 1(1), DOI: 10.1021/m900002k.
2009
- Predicting Promiscuity. Andrew L. Hopkins, Nature (2009) 462(7270), 167-168.
2008
- Network Pharmacology: The next paradigm in drug discovery. Andrew L. Hopkins. Nature Chemical Biology, (2008), 4(11), 682-690
- Genomic-scale prioritization of drug targets: The TDR targets database. Fernan Aguero, Bissan Al-Lazikani, Martin Aslett, Matthew Berriman, Frederick S. Buckner, Robert K. Campbell, Santiago Carmona, Ian M. Carruthers, A.W. Edith Chan, Feng Chen, Gregory J. Crowther, Maria A. Doyle, Christiane Hertz-Fowler, Andrew L. Hopkins, Gregg McAllister, Solomon Nwaka, John P. Overington, Arnab Pain, Gaia V. Paolini, Ursula Pieper, Stuart A. Ralph, Aaron Riechers, David S. Roos, Andrej Sali, Dhanasekaran Shanmugam, Wesley C. Van Voorhis and Christophe L.M.J. Verlinde, Nature Reviews Drug Discovery, (2008), 7(11), 900-7
pre-2007
- How many drug targets are there? John P. Overington, Bissan Al-Lazikani and Andrew L. Hopkins, Nature Rev. Drug Disc. (2006) 5(12), 993-996
- Global Mapping of Pharmacological Space. Gaia V. Paolini, Richard H.B. Shapland, Willem P. van Hoorn, Jonathan S. Mason and Andrew L. Hopkins, Nature Biotechnology. (2006), 24(7), 805-815.
- Can we rationally design promiscuous drugs? Andrew L. Hopkins, Jonathan S. Mason and John P. Overington, Curr. Op. Struct. Biol. (2006) 16, 127-136.
- Navigating Chemical Space for Biology and Medicine. Christopher Lipinski and Andrew Hopkins, Nature (2004), 432 (7019), 855-861.
- Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. Part I. Andrew L. Hopkins, John Milton, Jingshan Ren, Richard J. Hazen, Joseph H. Chan, David K. Stammers and David I. Stuart, J. Med. Chem. (2004), 47(24), 5923-5936
- The Druggable Genome. Andrew L. Hopkins and Colin R. Groom, Nature Rev. Drug Disc. (2002), 1 (9), 727-730